181 related articles for article (PubMed ID: 38568467)
21. Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
Wong EY; Kroon L
Clin Diabetes; 2021 Oct; 39(4):415-423. PubMed ID: 34866783
[TBL] [Abstract][Full Text] [Related]
22. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
[TBL] [Abstract][Full Text] [Related]
23. Novel insulins: expanding options in diabetes management.
Gerich JE
Am J Med; 2002 Sep; 113(4):308-16. PubMed ID: 12361817
[TBL] [Abstract][Full Text] [Related]
24. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2010 Mar; 4(2):419-28. PubMed ID: 20307403
[TBL] [Abstract][Full Text] [Related]
25. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
26. [An update on multiple insulin injection therapy in type 1 and 2 diabetes].
Varanauskiene E; Varanauskaite I; Ceponis J
Medicina (Kaunas); 2006; 42(9):770-9. PubMed ID: 17028476
[TBL] [Abstract][Full Text] [Related]
27. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
28. The dual-wave bolus feature in continuous subcutaneous insulin infusion pumps controls prolonged post-prandial hyperglycaemia better than standard bolus in Type 1 diabetes.
Lee SW; Cao M; Sajid S; Hayes M; Choi L; Rother C; de León R
Diabetes Nutr Metab; 2004 Aug; 17(4):211-6. PubMed ID: 15575341
[TBL] [Abstract][Full Text] [Related]
29. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.
Roach P
Clin Pharmacokinet; 2008; 47(9):595-610. PubMed ID: 18698880
[TBL] [Abstract][Full Text] [Related]
30. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
Ulrich H; Snyder B; Garg SK
Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
[TBL] [Abstract][Full Text] [Related]
31. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.
Hartman I
Clin Med Res; 2008 Sep; 6(2):54-67. PubMed ID: 18801953
[TBL] [Abstract][Full Text] [Related]
32. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P; Hramiak I
Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
[TBL] [Abstract][Full Text] [Related]
33. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
[TBL] [Abstract][Full Text] [Related]
34. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
Pozzilli P; Battelino T; Danne T; Hovorka R; Jarosz-Chobot P; Renard E
Diabetes Metab Res Rev; 2016 Jan; 32(1):21-39. PubMed ID: 25865292
[TBL] [Abstract][Full Text] [Related]
35. Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia.
Bolli GB
Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):13-20. PubMed ID: 19667675
[TBL] [Abstract][Full Text] [Related]
36. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
Reynolds NA; Wagstaff AJ
Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
[TBL] [Abstract][Full Text] [Related]
37. Optimal prandial timing of bolus insulin in diabetes management: a review.
Slattery D; Amiel SA; Choudhary P
Diabet Med; 2018 Mar; 35(3):306-316. PubMed ID: 29044708
[TBL] [Abstract][Full Text] [Related]
38. [Fast-acting insulin - new developments towards more flexibility for the patient].
Schmeisl GW; Kretzschmar Y
MMW Fortschr Med; 2016 Dec; 158(Suppl 6):5-11. PubMed ID: 27933575
[TBL] [Abstract][Full Text] [Related]
39. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart.
Ceriello A; Cavarape A; Martinelli L; Da Ros R; Marra G; Quagliaro L; Piconi L; Assaloni R; Motz E
Diabet Med; 2004 Feb; 21(2):171-5. PubMed ID: 14984453
[TBL] [Abstract][Full Text] [Related]
40. Advances in newer basal and bolus insulins: impact on type 1 diabetes.
Vliebergh J; Lefever E; Mathieu C
Curr Opin Endocrinol Diabetes Obes; 2021 Feb; 28(1):1-7. PubMed ID: 33315628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
